Skip to main content
. 2021 Dec 7;8(6):ENEURO.0341-21.2021. doi: 10.1523/ENEURO.0341-21.2021

Figure 6.

Figure 6.

Effects of intra-PrL infusions of the 5-HT2C receptor agonist RS 102221 in (A) risk-preferring animals (n =5) and (B) optimal decision-makers (n =6) on P1–P4 choice. Antagonism of the 5-HT2C receptor in the PrL did not significantly increase or decrease choice of any particular option in either risk-preferring (A) or optimal (B) rats. Data are expressed as mean ± SEM.